New treatment options for lupus – a focus on belimumab

Belimumab is the first biologic approved for patients with systemic lupus erythematosus (SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating factors or their receptors to reach the market. Its target, BLyS, also known as BAFF (B cell-activating factor from the tumor necr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiche, Laurent, Jourde, Noémie, Thomas, Guillemette, Bardin, Nathalie, Bornet, Charleric, Darque, Albert, Mancini, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277870/
https://www.ncbi.nlm.nih.gov/pubmed/22346356
http://dx.doi.org/10.2147/TCRM.S19819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277870/
https://www.ncbi.nlm.nih.gov/pubmed/22346356
http://dx.doi.org/10.2147/TCRM.S19819

Ejemplares similares